A new study from Israel found that the risk of developing myocarditis among males ages 16 to 19 years was about 1 in 15,000 after third dose of the Pfizer-BioNTech COVID-19 vaccine, and the cases were rare and mild, according to new research published today in the American Heart Association’s flagship journal Circulation.
- Read more about Myocarditis after COVID-19 vaccines remain rare
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2022/myocarditis-after-covid-19-vaccines-remain-rare
No comments:
Post a Comment